174 related articles for article (PubMed ID: 37308126)
1. Private Payer and Medicare Coverage Policies for Use of Circulating Tumor DNA Tests in Cancer Diagnostics and Treatment.
Douglas MP; Ragavan MV; Chen C; Kumar A; Gray SW; Blakely CM; Phillips KA
J Natl Compr Canc Netw; 2023 Jun; 21(6):609-616.e4. PubMed ID: 37308126
[TBL] [Abstract][Full Text] [Related]
2. Private Payer and Medicare Coverage for Circulating Tumor DNA Testing: A Historical Analysis of Coverage Policies From 2015 to 2019.
Douglas MP; Gray SW; Phillips KA
J Natl Compr Canc Netw; 2020 Jul; 18(7):866-872. PubMed ID: 32634780
[TBL] [Abstract][Full Text] [Related]
3. Eligibility criteria in private and public coverage policies for BRCA genetic testing and genetic counseling.
Wang G; Beattie MS; Ponce NA; Phillips KA
Genet Med; 2011 Dec; 13(12):1045-50. PubMed ID: 21844812
[TBL] [Abstract][Full Text] [Related]
4. Making the Rounds: Exploring the Role of Circulating Tumor DNA (ctDNA) in Non-Small Cell Lung Cancer.
Shields MD; Chen K; Dutcher G; Patel I; Pellini B
Int J Mol Sci; 2022 Aug; 23(16):. PubMed ID: 36012272
[TBL] [Abstract][Full Text] [Related]
5. Circulating tumor DNA minimal residual disease in clinical practice of non-small cell lung cancer.
Xia J; Zhang J; Xiong Y; Zhao J; Zhou Y; Jiang T; Zhu J
Expert Rev Mol Diagn; 2023; 23(10):913-924. PubMed ID: 37702546
[TBL] [Abstract][Full Text] [Related]
6. Detection and Quantification of ctDNA for Longitudinal Monitoring of Treatment in Non-Small Cell Lung Cancer Patients Using a Universal Mutant Detection Assay by Denaturing Capillary Electrophoresis.
Benesova L; Ptackova R; Halkova T; Semyakina A; Svaton M; Fiala O; Pesek M; Minarik M
Pathol Oncol Res; 2022; 28():1610308. PubMed ID: 35837614
[No Abstract] [Full Text] [Related]
7. Budget Impact Analysis of Circulating Tumor DNA Testing for Colon Cancer in Commercial Health and Medicare Advantage Plans.
Li Y; Heer AK; Sloane HS; Edelstein DL; Tie J; Gibbs P; Barzi A
JAMA Health Forum; 2024 May; 5(5):e241270. PubMed ID: 38819797
[TBL] [Abstract][Full Text] [Related]
8. Insurance Coverage Policies for Pharmacogenomic and Multi-Gene Testing for Cancer.
Lu CY; Loomer S; Ceccarelli R; Mazor KM; Sabin J; Clayton EW; Ginsburg GS; Wu AC
J Pers Med; 2018 May; 8(2):. PubMed ID: 29772692
[TBL] [Abstract][Full Text] [Related]
9. Variation in Private Payer Coverage of Rheumatoid Arthritis Drugs.
Chambers JD; Wilkinson CL; Anderson JE; Chenoweth MD
J Manag Care Spec Pharm; 2016 Oct; 22(10):1176-81. PubMed ID: 27668566
[TBL] [Abstract][Full Text] [Related]
10. [Application Value of ctDNA-based MRD Dedection
in Early Stage Non-small Cell Lung Cancer after Radical Surgery].
Dou S; Xie H; Yang L
Zhongguo Fei Ai Za Zhi; 2021 Dec; 24(12):862-866. PubMed ID: 34743498
[TBL] [Abstract][Full Text] [Related]
11. Perioperative ctDNA-Based Molecular Residual Disease Detection for Non-Small Cell Lung Cancer: A Prospective Multicenter Cohort Study (LUNGCA-1).
Xia L; Mei J; Kang R; Deng S; Chen Y; Yang Y; Feng G; Deng Y; Gan F; Lin Y; Pu Q; Ma L; Lin F; Yuan Y; Hu Y; Guo C; Liao H; Liu C; Zhu Y; Wang W; Liu Z; Xu Y; Li K; Li C; Li Q; He J; Chen W; Zhang X; Kou Y; Wang Y; Wu Z; Che G; Chen L; Liu L
Clin Cancer Res; 2022 Aug; 28(15):3308-3317. PubMed ID: 34844976
[TBL] [Abstract][Full Text] [Related]
12. Accuracy of minimal residual disease detection by circulating tumor DNA profiling in lung cancer: a meta-analysis.
Zhong R; Gao R; Fu W; Li C; Huo Z; Gao Y; Lu Y; Li F; Ge F; Tu H; You Z; He J; Liang W
BMC Med; 2023 May; 21(1):180. PubMed ID: 37173789
[TBL] [Abstract][Full Text] [Related]
13. Circulating tumor DNA integrating tissue clonality detects minimal residual disease in resectable non-small-cell lung cancer.
Wang S; Li M; Zhang J; Xing P; Wu M; Meng F; Jiang F; Wang J; Bao H; Huang J; Ren B; Yu M; Qiu N; Li H; Yuan F; Zhang Z; Jia H; Lu X; Zhang S; Wang X; Xu Y; Xia W; Liu T; Xu W; Xu X; Sun M; Wu X; Shao Y; Wang Q; Dai J; Qiu M; Wang J; Zhang Q; Xu L; Shen H; Yin R
J Hematol Oncol; 2022 Oct; 15(1):137. PubMed ID: 36183093
[TBL] [Abstract][Full Text] [Related]
14. Residual ctDNA after treatment predicts early relapse in patients with early-stage non-small cell lung cancer.
Gale D; Heider K; Ruiz-Valdepenas A; Hackinger S; Perry M; Marsico G; Rundell V; Wulff J; Sharma G; Knock H; Castedo J; Cooper W; Zhao H; Smith CG; Garg S; Anand S; Howarth K; Gilligan D; Harden SV; Rassl DM; Rintoul RC; Rosenfeld N
Ann Oncol; 2022 May; 33(5):500-510. PubMed ID: 35306155
[TBL] [Abstract][Full Text] [Related]
15. Early assessment of circulating tumor DNA after curative-intent resection predicts tumor recurrence in early-stage and locally advanced non-small-cell lung cancer.
Waldeck S; Mitschke J; Wiesemann S; Rassner M; Andrieux G; Deuter M; Mutter J; Lüchtenborg AM; Kottmann D; Titze L; Zeisel C; Jolic M; Philipp U; Lassmann S; Bronsert P; Greil C; Rawluk J; Becker H; Isbell L; Müller A; Doostkam S; Passlick B; Börries M; Duyster J; Wehrle J; Scherer F; von Bubnoff N
Mol Oncol; 2022 Jan; 16(2):527-537. PubMed ID: 34653314
[TBL] [Abstract][Full Text] [Related]
16. The Role and Impact of Minimal Residual Disease in NSCLC.
Frisone D; Friedlaender A; Addeo A
Curr Oncol Rep; 2021 Nov; 23(12):136. PubMed ID: 34735646
[TBL] [Abstract][Full Text] [Related]
17. High concordance of actionable genomic alterations identified between circulating tumor DNA-based and tissue-based next-generation sequencing testing in advanced non-small cell lung cancer: The Korean Lung Liquid Versus Invasive Biopsy Program.
Park S; Olsen S; Ku BM; Lee MS; Jung HA; Sun JM; Lee SH; Ahn JS; Park K; Choi YL; Ahn MJ
Cancer; 2021 Aug; 127(16):3019-3028. PubMed ID: 33826761
[TBL] [Abstract][Full Text] [Related]
18. Circulating tumor DNA-minimal residual disease: An up-and-coming nova in resectable non-small-cell lung cancer.
Li FQ; Cui JW
Crit Rev Oncol Hematol; 2022 Nov; 179():103800. PubMed ID: 36031171
[TBL] [Abstract][Full Text] [Related]
19. Identification and monitoring of somatic mutations in circulating cell-free tumor DNA in lung cancer patients.
Francaviglia I; Magliacane G; Lazzari C; Grassini G; Brunetto E; Dal Cin E; Girlando S; Medicina D; Smart CE; Bulotta A; Gregorc V; Pecciarini L; Doglioni C; Cangi MG
Lung Cancer; 2019 Aug; 134():225-232. PubMed ID: 31319985
[TBL] [Abstract][Full Text] [Related]
20. Circulating tumor DNA detection is correlated to histologic types in patients with early-stage non-small-cell lung cancer.
Zhang B; Niu X; Zhang Q; Wang C; Liu B; Yue D; Li C; Giaccone G; Li S; Gao L; Zhang H; Wang J; Yang H; Wu R; Ni P; Wang C; Ye M; Liu W
Lung Cancer; 2019 Aug; 134():108-116. PubMed ID: 31319968
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]